Third Quarter 2024 Results
Bayer Q3 2024 Media Update
Strategic progress in challenging business environment – Group outlook confirmed in nearly all parameters
- Group sales at 9.968 billion euros (Fx & portfolio adj. plus 0.6 percent)
- EBITDA before special items at 1.251 billion euros (minus 25.8 percent)
- Core earnings per share at 0.24 euros (minus 36.8 percent)
- Net income at minus 4.183 billion euros, impairment losses at Crop Science
- Free cash flow at 1.148 billion euros
- 2024 Group outlook confirmed for sales growth (Fx & portfolio adj.), core earnings per share and free cash flow – reduced market dynamics in agricultural business, lower growth expected for consumer health market, Pharmaceuticals at higher end of guidance
- 2025: Regulatory challenges and generic price pressure in crop protection business, new products to mitigate patent loss impact in Pharmaceuticals, robust growth expected at Consumer Health
- Successful advancements in bolstering the Pharmaceuticals pipeline and leveraging the new operating model
- Bill Anderson: “We're tackling challenges head on and making progress on our strategic priorities”